Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Source: Streetwise Reports (11/22/2024)
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.
read more >
Biotech Initiates Phase III Trial for Heart Disease Drug
Source: Streetwise Reports (11/20/2024)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.
read more >
Analyst Says Biotech's Data Supports Advancement Into Phase III
Source: Dr. Douglas Loe (11/19/2024)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
read more >
Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions
Source: Streetwise Reports (11/15/2024)
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.
read more >
Opportunity Arises for Co. With Cell Pouch
Source: Dr. Douglas Loe (11/12/2024)
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.
read more >